BBLG — Bone Biologics Cashflow Statement
0.000.00%
Last trade - 00:00- $2.36m
- -$0.96m
Annual cashflow statement for Bone Biologics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1.82 | -1.61 | -1.48 | -8.95 | -4.11 |
| Depreciation | |||||
| Non-Cash Items | 0.998 | 0.703 | -1.91 | -0.74 | 0.138 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.4 | -0.32 | -0.168 | 0.133 | -0.15 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -0.427 | -1.23 | -3.57 | -9.56 | -4.12 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.403 | 7.9 | 4.43 | 5.04 | 4.42 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.024 | 6.68 | 0.863 | -4.51 | 0.299 |